| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | ||
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-45,929 | -49,301 | -46,367 | -67,195 | -64 | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation of property and equipment | ||||||
1,264 | 1,900 | 2,041 | 1,680 | - | ||
Amortization of financing costs | ||||||
21 | 20 | 4,402 | 4,632 | - | ||
Noncash interest expense | ||||||
4,162 | 4,438 | 7,760 | 11,647 | - | ||
Share-based compensation expense | ||||||
4,057 | 5,583 | 3,792 | 5,425 | - | ||
Obsolete inventory reserve | ||||||
- | - | 898 | - | - | ||
Offering costs (including 2014 capitalized IPO costs) | ||||||
- | - | - | 3,978 | - | ||
Change in fair value of derivative liabilities | ||||||
0 | 221 | -549 | 443 | - | ||
Bad debt expense | ||||||
0 | 16 | 154 | - | - | ||
Impairment of assets | ||||||
0 | 3,711 | 28 | - | - | ||
Sales return provision | ||||||
158 | 0 | - | - | - | ||
Changes in: | ||||||
Accounts receivable | ||||||
2,303 | 529 | 474 | 465 | - | ||
Other receivables | ||||||
0 | 69 | -320 | 184 | - | ||
Accounts payable, related party | ||||||
- | - | - | - | 35 | ||
Interest payable | ||||||
- | - | - | - | 0 | ||
Inventories | ||||||
-1,281 | -1,279 | -1,400 | 1,196 | -0 | ||
Deferred cost of goods sold | ||||||
0 | -151 | -173 | 50 | - | ||
Prepaid expense and other current assets | ||||||
324 | 65 | -166 | -99 | - | ||
Other assets | ||||||
264 | -5 | -126 | -45 | - | ||
Amortization of debt discount | ||||||
- | - | - | - | 3 | ||
Deferred offering costs | ||||||
- | - | - | - | -10 | ||
Accounts payable | ||||||
-1,017 | 1,053 | -2,828 | 3,343 | 15 | ||
Accrued expense | ||||||
1,949 | 279 | -424 | -1,525 | - | ||
Deferred revenue | ||||||
- | - | -272 | 263 | - | ||
Deferred revenue | ||||||
0 | 15 | - | - | - | ||
Deferred rent liability | ||||||
51 | -12 | -73 | -55 | - | ||
Net cash provided by financing activities | ||||||
- | - | 36,777 | 23,716 | - | ||
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | 7,077 | -18,155 | - | ||
Net cash used in operating activities | ||||||
-37,190 | -31,970 | - | - | -21 | ||
Net cash used in operating activities | ||||||
- | - | -29,661 | -40,884 | - | ||
Investing activities | ||||||
Proceeds from sales of property and equipment | ||||||
0 | 185 | 134 | - | - | ||
Acquisition of property and equipment | ||||||
1,552 | 877 | 173 | 987 | - | ||
Net cash used in investing activities | ||||||
-1,552 | -692 | - | - | - | ||
Net cash used in investing activities | ||||||
- | - | -39 | -987 | - | ||
Financing activities | ||||||
Repayment of finance lease | ||||||
97 | 0 | 26 | 153 | - | ||
Investor capital contributions | ||||||
- | - | - | 17,982 | - | ||
Proceeds from issuance of common stock and exercise of warrants, net of fees | ||||||
57,294 | 48,792 | 23,964 | - | 15 | ||
Proceeds from issuance of common stock through purchase agreements, net of issuance costs | ||||||
3,106 | 0 | - | - | - | ||
Proceeds from issuance of common stock through ESPP | ||||||
236 | 0 | - | - | - | ||
Proceeds from issuance of Series AB ($5,819 received from related party CRG in 2016) | ||||||
- | - | 5,819 | 8,549 | - | ||
Proceeds from exercise of warrants by a related party | ||||||
- | - | 7,375 | - | - | ||
Common stock issuance costs | ||||||
- | - | - | 244 | - | ||
Offering costs | ||||||
- | - | - | 2,418 | - | ||
Costs associated with debt restructuring | ||||||
0 | 35 | 355 | - | - | ||
Proceeds from convertible notes | ||||||
- | - | - | - | 15 | ||
Proceeds from loan payable | ||||||
- | - | - | - | 0 | ||
Net cash provided by financing activities | ||||||
60,539 | 48,757 | - | - | 30 | ||
Net increase in cash, cash equivalents, and restricted cash | ||||||
21,797 | 16,095 | - | - | - | ||
Increase (decrease) in cash and cash equivalents | ||||||
- | - | - | - | 8 | ||
Supplemental disclosures of cash flow information | ||||||
Gain on sale of property and equipment | ||||||
-20 | 175 | 134 | - | - | ||
Reclassification of derivative liability upon exercise of warrants | ||||||
- | - | 1,557 | - | - | ||
Cancellation of derivative liability | ||||||
- | - | -3,036 | - | - | ||
Exchange of debt to Series B Preferred Stock | ||||||
- | - | 17,934 | - | - | ||
Commitment fee for Second Purchase Agreement | ||||||
429 | 411 | 0 | - | - | ||
Deferred revenue reduction | ||||||
1,638 | 0 | - | - | - | ||
Deferred cost of goods sold reduction | ||||||
539 | 0 | - | - | - | ||
Accrued distribution fees and managed care costs | ||||||
343 | 0 | - | - | - | ||
Noncash investing and financing | ||||||
Capital lease obligation | ||||||
360 | 0 | - | - | - | ||
Accounts payable and accrued offering costs | ||||||
396 | 0 | - | - | - | ||
Accrued/payable offering costs | ||||||
- | - | - | 405 | - | ||
Write off of debt issuance costs | ||||||
0 | 107 | 0 | - | - | ||
Related party conversion of debt to Series A preferred stock | ||||||
0 | 27,500 | 0 | - | - | ||
Treasury Stock, Value, Acquired, Cost Method | ||||||
0 | 24 | 0 | - | - | ||
Issuance of Series AB Preferred Stock warrants | ||||||
- | - | 4,000 | - | - | ||
Property and equipment additions included in accounts payable | ||||||
- | - | 25 | - | - | ||
Accrued issuance costs | ||||||
- | - | - | 160 | - | ||